Antiplatelet prescribing patterns for TIA and ischemic stroke: The Indiana University experience

Journal of the Neurological Sciences

Volumn 207, Issue 1-2, 2003, Pages 5-10

  Mayer, Thomas O ^a   Biller, José ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiplatelets; Ischemic stroke; TIA

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY RISK; DRUG MEGADOSE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEUROLOGIC DISEASE; OPTIMAL DRUG DOSE; PRESCRIPTION; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; AGED, 80 AND OVER; CEREBROVASCULAR ACCIDENT; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INDIANA; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES;

EID: 12244259062     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00348-9     Document Type: Conference Paper

References (33)

1. Fuster V., Dyken M.L., Vokonas P.S.et al. Aspirin as a therapeutic agent in cardiovascular disease. American Heart Association Scientific Statement. 1993;659-675 American Heart Association, Dallas.
2. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308:1994;81-106.
3. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet. 349:1997;1569-1581.
4. CAST: randomised, placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 349:1997;1641-1649.
5. Taylor D.W., Barnett H.J., Haynes R.B.et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet. 353:1999;2179-2184.
6. Gent M., Blakely J.A., Easton J.D.et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1:1989;1215-1220.
7. Hass W.K., Easton J.D., Adams H.P. Jr.et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. New Engl. J. Med. 321:1989;501-507.
8. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348:1996;1329-1339.
9. Diener H.C., Cunha L., Forbes C.et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143:1996;1-13.
10. Diener H.C. Dipyridamole trials in stroke prevention. Neurology. 51:1998;S17-S19.
11. Dyken M.L., Barnett H.J., Easton J.D.et al. Low-dose aspirin and stroke. "It ain't necessarily so" [editorial] Stroke. 23:1992;1395-1399.
12. Hart R.G., Harrison M.J. Aspirin wars: the optimal dose of aspirin to prevent stroke. Stroke. 27:1996;585-587.
13. Johnson E.S., Lanes S.F., Wentworth C.E. IIIet al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch. Intern. Med. 159:1999;1248-1253.
14. Hankey G.J., Sudlow C.L.M., Dunbabin D.W. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients (Cochrane Review). Cochrane Library. 2000;2.
15. Sharis J., Cannon C., Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann. Intern. Med. 129:1998;394-405.
16. Dyken M.L. Antiplatelet agents and stroke prevention. Semin. Neurol. 18:1998;441-450.
17. Fleck J.D., Biller J. Choices in medical management for prevention of acute ischemic stroke. Curr. Neurol. Neurosci. Rep. 1:2001;33-38.
18. Gorelick P.B., Born G.V., D'agostino R.B.et al. Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel. Stroke. 30:1999;1716-1721.
19. Diener H.C. Antiplatelet drugs in secondary prevention of stroke. Int. J. Clin. Practice. 52:1998;91-97.
20. McCabe D.J.H., Brown M.M. Prevention of ischaemic stroke - antiplatelets. Br. Med. Bull. 56:2000;510-525.
21. Weksler B.B. Antiplatelet agents in stroke prevention. Combination therapy: present and future. Cerebrovasc. Dis. 10(suppl. 5):2000;41-48.
22. Paciaroni M., Bogouusslavsky J. Clopidogrel for cerebrovascular prevention. Cerebrovasc. Dis. 9:1999;253-260.
23. Bhatt D.L., Kapadia S.R., Yadav J.S., Topol E.J. Update on clinical trials of antiplatelet therapy for cerebrovascular diseases. Cerebrovasc. Dis. 10(suppl. 5):2000;34-40.
24. Biller J., Love B.B., Gordon D.L. Antithrombotic therapy for ischemic cerebrovascular disease. Semin. Neurol. 11:1991;353-367.
25. Albers G.W., Amarenco P., Easton J.D., Sacco R.L., Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 119:2001;300S-320S.
26. Barnett H.J.M., Eliasziw M., Meldrum H.E. Drugs and surgery in the prevention of ischemic stroke. New Engl. J. Med. 332:1995;238-248.
27. Wysowksi D.K., Bacsanyi J. Blood dyscrasias and hematologic reactions in ticlopidine users. [letter] JAMA. 276:1996;952.
28. Bennett C.L., Connors J.M., Carwile J.M.et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. New Engl. J. Med. 342:2000;1773-1777.
29. Mehta S.R., Yusuf S., Peters R.J.et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 358:2001;527-533.
30. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-Segment elevation. New Engl. J. Med. 345:2001;494-502.
31. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 324:2002;71-86.
32. Albers G.W., Hart R.G., Lutsep H.L.et al. Supplement to the guidelines for the management of transient ischemic attacks. A statement from the ad hoc committee on guidelines for the management of transient ischemic attacks, stroke council, American Heart Association. Stroke. 30:1999;2502-2511.
33. Mohr J.P., Thompson J.L.P., Lazar R.M.et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. New Engl. J. Med. 345:2001;1444-1451.